Apparently APN01 is potentially a far better drug than CX-717. The argument that this indication is too difficult to create study now holds little water. Either poor marketing by Cor management or a poor molecule. You decide. With a potential $330 million payday, future trial design does not appear an issue, but clearly for Cor it's another phantom excuse. Not to mention the so called tightening of BP's partnering belt.
Market Data 
Markets 
AI
